title: A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment.
authors.forename: Françoise
authors.initials: F
authors.lastname: Isnard
authors.forename: Patrick
authors.initials: P
authors.lastname: Tilleul
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Laporte
authors.forename: Patrice
authors.initials: P
authors.lastname: Chevallier
authors.forename: Arnaud
authors.initials: A
authors.lastname: Pigneux
authors.forename: Antoine
authors.initials: A
authors.lastname: Lafuma
authors.forename: Lamine
authors.initials: L
authors.lastname: Mahi
authors.forename: Gilbert
authors.initials: G
authors.lastname: Deray
mesh_terms: D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004337:Drug Carriers; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000382:microbiology*; D007674:Kidney Diseases / Q000209:etiology / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy / Q000517:prevention & control; D009503:Neutropenia / Q000188:drug therapy*
chemical_list: D000935:Antifungal Agents; D004337:Drug Carriers; D000666:Amphotericin B